Camber Launches Eletriptan Hydrobromide Tablets
Camber Pharmaceuticals continues to strengthen its range of treatment options with the introduction of Eletriptan Hydrobromide Tablets [EL-e-TRIP-tan].
Eletriptan Hydrobromide Tablets are indicated for the acute treatment of migraine, with or without aura in adults.
Eletriptan Hydrobromide Tablets are available in:
|
Strength |
Size |
| 20 mg |
6 (1 x 6) Unit-dose Tablets |
| 40 mg |
6 (1 x 6) Unit-dose Tablets |
To learn more about this product, visit: www.camberpharma.com/eletriptan-hydrobromide
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






